Cephalon AI is a Taiwan-based healthcare technology company revolutionizing emergency medical care through AI-powered clinical workflow solutions. Our platform addresses a critical challenge in acute care: data fragmentation across imaging systems, EMRs, lab results, and clinical notes that delays life-saving decisions.

By leveraging FHIR-native architecture and real-time data synchronization, Cephalon compresses diagnostic cycles from 60–120 minutes to just 3–5 minutes for time-critical conditions including stroke, sepsis, and cardiac events. Unlike point-solutions that analyze only images, we provide seamless integration of full clinical context, enabling faster, more informed decision-making.

With proven deployments in Taiwan, expanding operations in Japan (156-hospital pipeline), and strategic U.S. market entry planned for 2026, Cephalon combines world-class AI research with practical healthcare commercialization. Led by Dr. Fan-pei Yang, a two-time National Innovation Award recipient, we're committed to returning time to the bedside and improving patient outcomes globally.

Cephalon AI delivers an AI-powered acute-care workflow platform that unifies fragmented medical data into a single, decision-ready interface. Our technology seamlessly integrates medical imaging (DICOM), electronic medical records, clinical notes, and laboratory results through FHIR-native architecture and HL7 orchestration.

Designed for time-critical conditions—stroke, sepsis, and cardiac emergencies—the platform uses advanced machine learning to automatically prioritize clinical findings, synchronize data in real-time, and deliver actionable prompts to clinicians.

Unlike point-solutions analyzing isolated data streams, our technology provides full clinical context by fusing structured and unstructured data. This eliminates manual searching and compresses diagnostic cycles from 60–120 minutes to 3–5 minutes.

Deployed via secure cloud or on-premises for low-latency performance, Cephalon ensures HIPAA compliance with rapid 90-day implementation—significantly faster than legacy systems requiring 12+ months.

1. Healthcare-focused VCs ($2M round) with FDA regulatory expertise and U.S. hospital networks. 

Priority: East Coast firms (Oak HC/FT, Transformation Capital, 7wireVentures) experienced in clinical workflow AI, FHIR-native platforms, and B2B healthcare SaaS. Strategic investors include health system venture arms and cross-border funds supporting Taiwan-U.S. expansion.

2. U.S. Operations Plan:

Establishing Delaware C-Corp (Q1 2026) with headquarters leveraging existing hospital networks. Pursuing FDA 510(k) clearance and HIPAA compliance. Initial team: GM, sales executives, customer success manager. Seeking assistance with: regulatory consultants, state incentives, office space, talent recruitment, tax/legal advisors, and clinical partnership introductions for pilot programs.

3. Target Customer Profile:

Regional hospitals (200-500 beds) in Arkansas with emergency departments handling stroke, sepsis, cardiac cases. Priority: Little Rock and surrounding areas. Seeking introductions to hospital CMIOs, CIOs, and emergency medicine directors. Initial targets include Baptist Health, CHI St. Vincent, UAMS Medical Center, and Arkansas regional networks requiring workflow optimization.